FibroGen (NASDAQ:FGEN) Announces Earnings Results

FibroGen (NASDAQ:FGEN) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.21, Zacks reports. The business had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the prior year, the firm earned ($0.52) earnings per share.

FibroGen Stock Down 14.7 %

Shares of FGEN traded down $0.06 during mid-day trading on Wednesday, hitting $0.33. The stock had a trading volume of 3,544,255 shares, compared to its average volume of 2,230,193. FibroGen has a fifty-two week low of $0.18 and a fifty-two week high of $2.93. The company has a market cap of $33.10 million, a PE ratio of -0.30 and a beta of 0.72. The company’s fifty day simple moving average is $0.37 and its two-hundred day simple moving average is $0.72.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on FGEN shares. William Blair restated a “market perform” rating on shares of FibroGen in a research note on Wednesday. StockNews.com initiated coverage on shares of FibroGen in a research report on Wednesday, November 6th. They issued a “hold” rating for the company.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.